Genialis is revolutionizing the fight against cancer by harnessing the complexity of human biology to bring precision to medicine. With a recent Series A funding round of $13 million and investors such as Redalpine, Taiwania Capital, First Star Ventures, Debiopharm, and P5 Health Ventures, Genialis is well-positioned to advance its mission. Founder Rafael Rosengarten has built a team at Genialis that puts people first, developing more effective drugs and allowing for more targeted treatment decisions for better patient outcomes. 

Genialis ResponderID™ is a biomarker discovery platform that employs a people-first framework to model underlying disease biology, leading to biomarkers that work in real patient populations and scale across clinical settings. Their proprietary technology and validated signatures, combined with human data, provide a powerful tool for the development of more effective drugs and better treatment decisions. Genialis' computational precision medicine is trusted by industry leaders around the globe, and its mission is to deliver benefits and hopes to patients and their families.